Related Experiment Videos
A new peptide from Crotalus atrox snake venom
Peptides
|January 1, 1985
Summary
Researchers discovered a novel hypotensive decapeptide, POL-236, in Crotalus atrox venom. This peptide, unrelated to ACE inhibition, impacts blood pressure through vascular and cardiac effects.
Area of Science:
- Pharmacology
- Biochemistry
- Toxicology
Background:
- Snake venoms are a rich source of bioactive peptides.
- Hypotensive peptides, particularly those not acting via Angiotensin-Converting Enzyme (ACE) inhibition, are of therapeutic interest.
- Investigating novel peptides from diverse snake families can yield new pharmacological agents.
Purpose of the Study:
- To screen 66 snake venoms for novel hypotensive peptides.
- To identify and characterize a new hypotensive peptide from Crotalus atrox venom.
- To investigate the pharmacological effects of the identified peptide on blood pressure.
Main Methods:
- Screening of 66 snake venoms (crotalid, viperid, elapid families).
- Isolation and characterization of a decapeptide (POL-236) from Crotalus atrox venom.
- Pharmacological assays on synthesized POL-236 to assess blood pressure effects.
Main Results:
- A novel decapeptide, POL-236 (PYR-LEU-TRP-PRO-ARG-PRO-GLN-ILE-PRO-PRO), was identified in Crotalus atrox venom.
- POL-236 exhibits hypotensive effects.
- These effects are likely mediated by vascular and cardiac mechanisms, independent of ACE inhibition.
Conclusions:
- Crotalus atrox venom contains a unique hypotensive decapeptide, POL-236.
- POL-236 represents a potential new class of blood pressure-regulating agents.
- Further research into POL-236's mechanism and therapeutic potential is warranted.